AstraZeneca plc (ADR) (AZN), Sanofi SA (ADR) (SNY), GlaxoSmithKline plc (ADR) (GSK): Is It Worth Getting a Flu Shot? The Answer May Surprise You…

Page 2 of 2

If simply 10% more of the population were to immunize themselves against the flu each year, these four companies would need to produce more than 30 million additional doses. This would be particularly beneficial for Sanofi SA (ADR) (NYSE:SNY)’s Fluzone, Novartis’ Fluvirin, and Glaxo’s vaccine and drug trio, which have predominantly ruled the flu market in 2012-2013.

The flu shot isn’t a perfect science, but it’s a collection of the best data researchers have at any given time that could help keep you out of the hospital and keep you healthier. It isn’t a cure-all, but it definitely can’t hurt your chances by getting immunized. Between the growth opportunity for vaccine makers, which could turn into a healthy investment return and better health all around, getting a flu shot never looked like a smarter idea!

A simple approach to investing
The best investing approach is to choose great companies and stick with them for the long term. The Motley Fool’s free report “
3 Stocks That Will Help You Retire Rich” names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Is It Worth Getting a Flu Shot? The Answer May Surprise You… originally appeared on Fool.com and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Page 2 of 2